Patent · US Expired

Component of von Hippel-Lindau tumor suppressor complex and SCF ubiquitin ligase

US6858709B1 · kind B1 · utility

4Cited by
0References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 25, 2000
Grant dateFeb 22, 2005
Priority date
Expiry dateFeb 25, 2020

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S530/835
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Rbx1, an evolutionarily conserved Cullin-interacting RING-H2 finger protein, has been discovered. Mammalian Rbx1 has been identified as a component of the CUL2-containing VHL complex. An Rbx1 homolog from S. cerevisiae has also been identified as a subunit and activator of the Cdc53-containing SCFCdc4 ubiquitin ligase required for ubiquitination of the cdk inhibitor Sic1 and for the G1/S cell cycle transition in yeast, providing a link between the multiprotein VHL tumor suppressor complex and cellular ubiquitination. The Rbx1 protein acts as a cellular marker useful (1) in detecting a possible predisposition to certain carcinomas, (2) as a molecular target for treating those carcinomas therapeutically. (3) as a target for inhibition by drugs that manipulate the growth of cells, and (4) as a research tool to better understand the various complex mechanisms of cell ubiquitination, binding of certain activator proteins, fibronectin deposition and other aspects of the cellular division process.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.